[{"orgOrder":0,"company":"Oscotec","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cevidoplenib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Not Applicable"},{"orgOrder":0,"company":"Oscotec","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cevidoplenib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Cevidoplenib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : SKI-O-703 (cevidoplenib) is a SYK inhibitor, small molecule drug candidate, which is being evaluated for the treatment of patients with immune thrombocytopenia.

                          Brand Name : SKI-O-703

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 21, 2024

                          Lead Product(s) : Cevidoplenib

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : SKI-O-592 (cevidoplenib) binds to and inhibits SYK activity, blocking Fc receptor and BCR-mediated signaling in inflammatory cells. This leads to the inhibition of the related inflammatory responses and tissue damage. It is being developed for immune thr...

                          Brand Name : SKI-O-592

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 24, 2023

                          Lead Product(s) : Cevidoplenib

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank